CXCL12 News and Research

RSS

Combining a chemical blocker of immune cell exit with immunotherapy stops skin cancer growth

The number of specialized immune cells available for fighting skin cancer doubled when a new treatment blocked their escape from melanoma tumors, experiments in mice and human cells show.

27 Feb 2023

Researchers develop a potential way to tackle one of the underlying causes of asthma

A possible way to tackle one of the underlying causes of asthma has been developed by researchers from Aston University and Imperial College London.

9 Aug 2022

Scientists identify innovative treatment approach for arterial thromboses

Scientists have shown in an animal model that the CXCL12 messenger could be suitable as a target structure for the treatment of blood-clotting disorders.

21 Apr 2022

Study shows how some cancer cells immobilize T cells

Our immune systems have the potential to find and destroy cancer cells. But cancer cells can be clever and develop tricks to evade the immune system.

16 Feb 2022

$Study finds new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma$

Study finds new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma

The final results from a national phase 2 study including researchers from Yale Cancer Center show the drug tipifarnib increased survival rates for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

13 Dec 2021

New class of CXCR4 antagonists could prevent airway inflammation and atopic dermatitis

Aberrant CXCR4/CXCL12 signaling is involved in many pathophysiological processes such as cancer and inflammatory diseases. A natural fragment of serum albumin, named EPI-X4, has previously been identified as endogenous peptide antagonist andinverse agonistof CXCR4 and is a promising compound for the development of improved analogues for the therapy of CXCR4-associated diseases.

18 Oct 2021

Study reveals a detrimental role of the immune system in Lewy body dementias

T-cells respond to buildups of alpha-synuclein, the aggregated protein clumps that are a feature of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease (PD), according to a Northwestern Medicine study published in Science.

14 Oct 2021

Cats with chronic kidney disease may help inform treatment for humans in future

The Wake Forest Institute for Regenerative Medicine is investigating how cats with chronic kidney disease could someday help inform treatment for humans.

13 Mar 2021

How does SARS-CoV-2 infect the pancreas?

To understand how SARS-CoV-2 infects the pancreas and investigate its effects, a team of researchers used the human iPSC (induced pluripotent stem cells)-derived pancreatic cultures and analyzed the post-infection cellular and molecular changes.

5 Feb 2021

New drug lures stem cells to damaged tissue, improves treatment efficacy

Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy--a scientific first and major advance for the field of regenerative medicine.

25 Nov 2020

Researchers discover key gene essential for survival of leukemia stem cells

Acute myeloid leukemia (AML) is one of the most common forms of blood cancer among adults and is associated with a low survival rate, and leads to the inhibition of normal blood formation.

3 Jun 2020

Shape-shifting cells rush to repair the defect after bone injury

Conventional thinking is that bone regeneration is left to a small number of mighty cells called skeletal stem cells, which reside within larger groups of bone marrow stromal cells.

29 Jan 2020

Encapsulating human beta cells with immune-repelling protein restores glucose metabolism in diabetic mice

Encapsulating human stem-cell-derived beta cells in microcapsules made with a protein that repels key immune cells restored glucose metabolism in diabetic mice and protected the cells from immune system attack, preventing the buildup of inflammatory fibrotic tissue that has plagued previous trials of encapsulated beta cells.

27 Mar 2019

Understanding maintenance of quiescent stem cells in chronic myelogenous leukemia

Most patients with chronic myelogenous leukemia can be treated with tyrosine kinase inhibitors. These drugs are highly effective and lead to deep remission and prolonged survival.

22 Mar 2019

Fibrosis-targeting drugs may benefit patients with late-stage, metastatic breast cancer

A Massachusetts General Hospital (MGH) research team has found that the overgrowth of connective called fibrosis may block the effectiveness of immunotherapies against metastatic breast cancer.

29 Jan 2019

Studies provide insight into molecular changes prior to onset of arthritis

The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR 2018) provide insight into molecular changes prior to the onset of arthritis which could inform future novel diagnostics and early therapeutic interventions.

18 Jun 2018

Researchers find new way to accelerate wound healing

Researchers at Uppsala University and SLU have found a new way of accelerating wound healing. The technology and the mode of action method published in the highly ranked journal PNAS involves using lactic acid bacteria as vectors to produce and deliver a human chemokine on site in the wounds.

5 Feb 2018

New research reveals possible therapeutic target for controlling inflammation in the brain

New research published online in the Journal of Leukocyte Biology showed for the first time that mature monocytes (a specific type of white blood cell) express the CXCR7 receptor on their surface.

3 Nov 2017

MGH researchers identify potential strategy for improving efficacy of angiogenesis inhibitors

A Massachusetts General Hospital research team has identified a potential strategy for improving the efficacy of angiogenesis inhibitors, drugs that help fight cancer by blocking the formation of new blood vessels.

13 Sep 2017

Drug could activate innate anti-tumor immunity to eradicate aggressive prostate cancer in mice

Cabozantinib, a drug already used to treat patients with certain types of thyroid or kidney cancer, was able to eradicate invasive prostate cancers in mice by causing tumor cells to secrete factors that entice neutrophils - the first-responders of the immune system - to infiltrate the tumor, where they triggered an immune response that led to tumor clearance.

9 Mar 2017